These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
286 related articles for article (PubMed ID: 9972969)
1. A pilot study: use of fludarabine for refractory dermatomyositis and polymyositis, and examination of endpoint measures. Adams EM; Pucino F; Yarboro C; Hicks JE; Thornton B; McGarvey C; Sonies BC; Bartlett ML; Villalba ML; Fleisher T; Plotz PH J Rheumatol; 1999 Feb; 26(2):352-60. PubMed ID: 9972969 [TBL] [Abstract][Full Text] [Related]
2. A pilot study of low-dose fludarabine in membranous nephropathy refractory to therapy. Boumpas DT; Tassiulas IO; Fleisher TA; Vaughan E; Piscitelli S; Kim Y; Pucino F; Balow JE; Austin HA Clin Nephrol; 1999 Aug; 52(2):67-75. PubMed ID: 10480216 [TBL] [Abstract][Full Text] [Related]
3. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Dastmalchi M; Grundtman C; Alexanderson H; Mavragani CP; Einarsdottir H; Helmers SB; Elvin K; Crow MK; Nennesmo I; Lundberg IE Ann Rheum Dis; 2008 Dec; 67(12):1670-7. PubMed ID: 18272672 [TBL] [Abstract][Full Text] [Related]
4. High dose versus low dose fludarabine in the treatment of patients with severe refractory rheumatoid arthritis. Davis JC; Fessler BJ; Tassiulas IO; McInnes IB; Yarboro CH; Pillemer S; Wilder R; Fleisher TA; Klippel JH; Boumpas DT J Rheumatol; 1998 Sep; 25(9):1694-704. PubMed ID: 9733448 [TBL] [Abstract][Full Text] [Related]
6. [Dermatomyositis and polymyositis: clinical aspects and treatment]. Hachulla E Ann Med Interne (Paris); 2001 Nov; 152(7):455-64. PubMed ID: 11965087 [TBL] [Abstract][Full Text] [Related]
7. Decreased expression of interleukin-1alpha, interleukin-1beta, and cell adhesion molecules in muscle tissue following corticosteroid treatment in patients with polymyositis and dermatomyositis. Lundberg I; Kratz AK; Alexanderson H; Patarroyo M Arthritis Rheum; 2000 Feb; 43(2):336-48. PubMed ID: 10693873 [TBL] [Abstract][Full Text] [Related]
8. Rituximab as therapy for refractory polymyositis and dermatomyositis. Noss EH; Hausner-Sypek DL; Weinblatt ME J Rheumatol; 2006 May; 33(5):1021-6. PubMed ID: 16541475 [TBL] [Abstract][Full Text] [Related]
9. Rituximab for refractory polymyositis: an open-label prospective study. Mok CC; Ho LY; To CH J Rheumatol; 2007 Sep; 34(9):1864-8. PubMed ID: 17722224 [TBL] [Abstract][Full Text] [Related]
10. Effects of immunosuppressive treatment on interleukin-15 and interleukin-15 receptor α expression in muscle tissue of patients with polymyositis or dermatomyositis. Zong M; Loell I; Lindroos E; Nader GA; Alexanderson H; Hallengren CS; Borg K; Arnardottir S; McInnes IB; Lundberg IE Ann Rheum Dis; 2012 Jun; 71(6):1055-63. PubMed ID: 22267334 [TBL] [Abstract][Full Text] [Related]
11. [The practice guideline 'Dermatomyositis, polymyositis and sporadic inclusion body myositis']. Hoogendijk JE; Bijlsma JW; van Engelen BG; Lindeman E; van Royen-Kerkhof A; de Rie MA; de Visser M; Jennekens FG; Ned Tijdschr Geneeskd; 2005 Sep; 149(38):2104-11. PubMed ID: 16201600 [TBL] [Abstract][Full Text] [Related]
13. Cyclosporin A in the treatment of refractory adult polymyositis/dermatomyositis: population based experience in 6 patients and literature review. Qushmaq KA; Chalmers A; Esdaile JM J Rheumatol; 2000 Dec; 27(12):2855-9. PubMed ID: 11128676 [TBL] [Abstract][Full Text] [Related]
14. Strength in polymyositis and dermatomyositis: best outcome in patients treated early. Fafalak RG; Peterson MG; Kagen LJ J Rheumatol; 1994 Apr; 21(4):643-8. PubMed ID: 8035387 [TBL] [Abstract][Full Text] [Related]
15. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Levine TD Arthritis Rheum; 2005 Feb; 52(2):601-7. PubMed ID: 15692974 [TBL] [Abstract][Full Text] [Related]
16. Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia. Tsimberidou AM; Keating MJ; Giles FJ; Wierda WG; Ferrajoli A; Lerner S; Beran M; Andreeff M; Kantarjian HM; O'Brien S Cancer; 2004 Jun; 100(12):2583-91. PubMed ID: 15197800 [TBL] [Abstract][Full Text] [Related]
17. Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population. Unger L; Kampf S; Lüthke K; Aringer M Rheumatology (Oxford); 2014 Sep; 53(9):1630-8. PubMed ID: 24706995 [TBL] [Abstract][Full Text] [Related]
18. Fludarabine + prednisone +/- alpha-interferon followed or not by alpha-interferon maintenance therapy for previously untreated patients with chronic lymphocytic leukemia: long term results of a randomized study. Mauro FR; Zinzani P; Zaja F; Gentile M; Vegna ML; Stefoni V; Marin L; Fanin R; Baccarani M; Tura S; Mandelli F Haematologica; 2003 Dec; 88(12):1348-57. PubMed ID: 14687987 [TBL] [Abstract][Full Text] [Related]
19. [Immunoglobulins or plasma exchange? New treatment methods in polymyositis and dermatomyositis: plasma exchange and intravenous immunoglobulins]. Chérin P; Herson S Ann Med Interne (Paris); 1993; 144(8):521-5. PubMed ID: 8179241 [TBL] [Abstract][Full Text] [Related]
20. Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate. Hengstman GJ; De Bleecker JL; Feist E; Vissing J; Denton CP; Manoussakis MN; Slott Jensen H; van Engelen BG; van den Hoogen FH Eur Neurol; 2008; 59(3-4):159-63. PubMed ID: 18230873 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]